Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,037 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,948 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06285370 | A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy | completed | Phase 4 | 23 | Kyowa Kirin China Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT04846855 | Regional Anesthesia for Totally Awake Upper Limb Surgery in PEDiatric Population(RATAPED) | completed | Phase 4 | 100 | GCS Ramsay Santé pour l'Enseignement et la RechercheOTHER |
| 1 |
| Jul 16, 2026 |
| clinicaltrials |
| NCT06035757 | The Occurrence of Emergence Agitation in Pediatric Strabismus Surgery | completed | Phase 4 | 76 | Konkuk University Medical CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT03934684 | Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma | completed | Phase 4 | 101 | AmgenINDUSTRY | 1 | May 11, 2026 | clinicaltrials |
| NCT02844309 | The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM(BDH-WM02) | completed | Phase 4 | 44 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT02844322 | The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia(BDH-WM01) | completed | Phase 4 | 35 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT02844361 | Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia(BDH-WM03) | completed | Phase 4 | 70 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT02858804 | EDOCH Alternating With DHAP for New Diagnosed Younger MCL(BDH-MCL01) | completed | Phase 4 | 55 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT04952766 | Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults(EREVA) | completed | Phase 4 | 196 | Centre Hospitalier Régional d'OrléansOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT05687032 | A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia | completed | Phase 4 | 44 | PfizerINDUSTRY | 1 | Dec 3, 2025 | clinicaltrials |
| NCT05511428 | Home Based Daratumumab Administration for Patients With Multiple Myeloma | completed | Phase 4 | 20 | Thomas Jefferson UniversityOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT01909934 | Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma | completed | Phase 4 | 50 | TakedaINDUSTRY | 10 | Sep 19, 2025 | clinicaltrials |
| NCT05442554 | A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma | completed | Phase 4 | 10 | TakedaINDUSTRY | 1 | Sep 18, 2025 | clinicaltrials |
| NCT03190330 | A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion | completed | Phase 4 | 75 | Johnson & Johnson Private LimitedINDUSTRY | 1 | May 25, 2025 | clinicaltrials |
| NCT04042376 | A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM) | completed | Phase 4 | 17 | Janssen Research & Development, LLCINDUSTRY | 1 | May 25, 2025 | clinicaltrials |
| NCT05555329 | Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day; the POMAlternative Study(POMAlternative) | completed | Phase 4 | 12 | Amsterdam UMC, location VUmcOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT05108805 | Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting | completed | Phase 4 | 25 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Mar 27, 2025 | clinicaltrials |
| NCT04080531 | Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders | completed | Phase 4 | 165 | Emory UniversityOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT01804166 | A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL) | completed | Phase 4 | 1 | Janssen Scientific Affairs, LLCINDUSTRY | 1 | Feb 4, 2025 | clinicaltrials |
| NCT03768960 | A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent | completed | Phase 4 | 150 | Johnson & Johnson Private LimitedINDUSTRY | 1 | Feb 3, 2025 | clinicaltrials |
| NCT04217967 | Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients | completed | Phase 4 | 211 | Peking Union Medical College HospitalOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT06425276 | Evaluate Safety and Efficacy of High-dose Melphalan HCL for Injection in MM Patients With Auto-HSC Transplantation | completed | Phase 4 | 67 | CASI Pharmaceuticals (China) Co., Ltd.INDUSTRY | 1 | May 23, 2024 | clinicaltrials |
| NCT00733538 | Stage I Multiple Myeloma Treatment(IFM-01-04) | completed | Phase 4 | 89 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT03817853 | An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma | completed | Phase 4 | 114 | Hoffmann-La RocheINDUSTRY | 7 | Apr 4, 2024 | clinicaltrials |
| NCT01735955 | Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study | completed | Phase 4 | 57 | Novartis PharmaceuticalsINDUSTRY | 16 | Feb 8, 2024 | clinicaltrials |
| NCT01088750 | Surgery Alone or With CYC VBL and PRED or CVP Alone in Stage IA or IIA Nodular Lymphocyte-Predominant Hodgkin Lymphoma(EuroNetLP1) | completed | Phase 4 | 225 | Christine Mauz-KörholzOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT03677596 | A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients | completed | Phase 4 | 102 | PfizerINDUSTRY | 8 | Nov 22, 2023 | clinicaltrials |
| NCT00168727 | Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma | completed | Phase 4 | 12 | BiogenINDUSTRY | 1 | Aug 23, 2023 | clinicaltrials |
| NCT05316831 | Immune Response After Pneumococcal Vaccination in Patient With Chronic Lymphocytic Leukemia | completed | Phase 4 | 77 | Region Örebro CountyOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT00198978 | German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | completed | Phase 4 | 377 | Goethe UniversityOTHER | 1 | Mar 20, 2023 | clinicaltrials |
| NCT00199056 | German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99) | completed | Phase 4 | 225 | Goethe UniversityOTHER | 1 | Mar 20, 2023 | clinicaltrials |
| NCT00199095 | Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia | completed | Phase 4 | 40 | Goethe UniversityOTHER | 1 | Mar 20, 2023 | clinicaltrials |
| NCT00199069 | German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93) | completed | Phase 4 | 720 | Goethe UniversityOTHER | 1 | Mar 17, 2023 | clinicaltrials |
| NCT02286830 | Prolonged Protection From Bone Disease in Multiple Myeloma(Magnolia) | completed | Phase 4 | 158 | Thomas LundOTHER | 1 | Feb 17, 2023 | clinicaltrials |
| NCT03318393 | Study Comparing Bivalirudin Versus Heparin in Neonatal and Pediatric ECMO | completed | Phase 4 | 30 | University of Texas Southwestern Medical CenterOTHER | 1 | Jan 31, 2023 | clinicaltrials |
| NCT03619252 | Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents | completed | Phase 4 | 36 | Minsk Scientific-Practical Center for Surgery, Transplantation and HematologyOTHER_GOV | 1 | Aug 31, 2022 | clinicaltrials |
| NCT00199082 | Newly Diagnosed Mature B-ALL, Burkitt's Lymphoma and Other High-grade Lymphoma in Adults | completed | Phase 4 | 650 | Nicola GoekbugetOTHER | 1 | Aug 19, 2022 | clinicaltrials |
| NCT00198991 | German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003) | completed | Phase 4 | 1,883 | Goethe UniversityOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT02447718 | Vaccinating Children After Chemotherapy | completed | Phase 4 | 156 | Canadian Immunization Research NetworkNETWORK | 1 | Jun 24, 2022 | clinicaltrials |
| NCT04349306 | Evaluate the Efficacy and Safety of Rasburicase (Fasturtec®) in the Prevention and Treatment of Hyperuricemia in Pediatric Patients With Non-Hodgkin's Lymphoma and Acute Leukemia(RAISE) | completed | Phase 4 | 50 | SanofiINDUSTRY | 1 | Apr 25, 2022 | clinicaltrials |
| NCT05176119 | Nalbuphine Versus Ketamine for Prevention of Emergence Agitation After Sevoflurane in Children Undergoing Tonsillectomy | completed | Phase 4 | 90 | Ain Shams UniversityOTHER | 1 | Jan 4, 2022 | clinicaltrials |
| NCT00622505 | Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants(Z-MARK) | completed | Phase 4 | 121 | Novartis PharmaceuticalsINDUSTRY | 1 | May 26, 2021 | clinicaltrials |
| NCT01990534 | A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma | completed | Phase 4 | 60 | Millennium Pharmaceuticals, Inc.INDUSTRY | 7 | Apr 9, 2021 | clinicaltrials |
| NCT03176849 | A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT | completed | Phase 4 | 49 | Phoenix Children's HospitalOTHER | 1 | Nov 17, 2020 | clinicaltrials |
| NCT00853008 | Treatment of High Risk Adult Acute Lymphoblastic Leukemia(LAL-AR/2003) | completed | Phase 4 | 100 | PETHEMA FoundationOTHER | 1 | Apr 7, 2020 | clinicaltrials |
| NCT01087008 | Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse(AZABACHE) | completed | Phase 4 | 103 | PETHEMA FoundationOTHER | 1 | Apr 6, 2020 | clinicaltrials |
| NCT01731886 | Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma | completed | Phase 4 | 60 | Columbia UniversityOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT02958969 | Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma | completed | Phase 4 | 50 | Gregory PiazzaOTHER | 1 | Dec 17, 2019 | clinicaltrials |
| NCT01007448 | Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL) | completed | Phase 4 | 59 | Bausch Health Americas, Inc.INDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT00003398 | Bone Marrow Transplantation in Treating Patients With Hematologic Cancer | completed | Phase 4 | 45 | University of Maryland, BaltimoreOTHER | 1 | Oct 17, 2019 | clinicaltrials |
Data updated 20 days agoSource updated Sep 9, 2026source: clinicaltrials